# Dose Ranging Study to Evaluate the Efficacy and Safety of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis

> **NCT01061723** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 301 (actual)

## Conditions studied

- Ankylosing Spondylitis

## Interventions

- **DRUG:** Sarilumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01061723
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 301 (ACTUAL)
- **Last updated:** 2017-08-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01061723

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01061723, "Dose Ranging Study to Evaluate the Efficacy and Safety of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01061723. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*